Month: July 2024

The 29th Annual Congress of the European Hematology Association (EHA) was held grandly in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Jia Wei's team from Tongji Hospital, Huazhong University of Science and Technology had multiple studies selected for poster or e-poster presentations. This issue focuses on two studies in the field of myeloid tumors. One study (P487), conducted in collaboration with Associate Professor Yu Xiaoxuan from Nanjing University of Chinese Medicine, explores the relationship between UBE2Q1 and AML prognosis and its mechanism of affecting antigen presentation in AML. The other study (P1885) investigates the clinical prognosis and molecular characteristics of MDS patients with ASXL1 mutations.

A research study led by Professor Wenyu Shi from the Affiliated Hospital of Nantong University and Dr. Yi Miao from The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial Hospital), under the Jiangsu Lymphoma Collaboration Group and the Jiangsu HLH Working Group, was selected for an oral presentation. This study is the first to show that the Endothelial Activation and Stress Index (EASIX) is a reliable predictor of outcomes in patients with T/NK cell lymphoma-associated hemophagocytic lymphohistiocytosis (T/NK-LA HLH).The 15th International T-Cell Lymphoma Forum successfully took place from June 6 to 8, 2024, in San Diego, USA. This forum brought together top clinicians, researchers, and distinguished representatives from the medical field worldwide, aiming to advance the research and innovation in T-cell lymphoma, ultimately improving patient survival and well-being.  "Oncology Frontier - Hematology Frontier" invited Professor Shi and Dr. Miao for an interview to share and interpret the study's content and significance.

From June 13 to 16, 2024, the 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's EHA meeting, a study (S119) by Professor Xian Zhang from Beijing Lu Daopei Hospital was selected for oral presentation. The study explored immune reconstitution in R/R T-ALL/LBL patients following CD7 CAR-T therapy. “Oncology Frontier - Hematology Frontier” interviewed Professor Xian Zhang to introduce and interpret the study's content and topics related to the treatment of R/R T-ALL/LBL.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.